BAM
PACB icon

Blueshift Asset Management’s Pacific Biosciences PACB Stock Holding History

Blueshift Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,318
Closed -$955K – 1225
2021
Q2 		$955K Buy
+27,318
New +$795K 0.05% 370
2020
Q1 		– Sell
-14,456
Closed -$74K – 537
2019
Q4 		$74K Buy
+14,456
New +$73.5K 0.01% 762
2019
Q3 		– Sell
-14,197
Closed -$86K – 895
2019
Q2 		$86K Sell
14,197
-2,056
-13% -$14.4K 0.01% 677
2019
Q1 		$118K Buy
+16,253
New +$118K 0.02% 641

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Blueshift Asset Management's PACB Position: Q3 2021 in Review

Blueshift Asset Management sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 27,318 shares — an estimated $955K sold.

Blueshift Asset Management first reported a position in PACB in Q1 2019 and held it in 4 quarters. The position peaked at $955K in Q2 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Blueshift Asset Management reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 27,318 Pacific Biosciences shares in Q3 2021, an estimated $955K.
  • Blueshift Asset Management first reported a position in Pacific Biosciences in Q1 2019 and held it in 4 quarters.
  • Blueshift Asset Management's Pacific Biosciences position peaked at $955K in Q2 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.